Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.67 +0.58 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified 
Via Benzinga
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced. 
Via Chartmill
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco. 
Via Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL is showing good growth, while it is not too expensive.
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
From Exelixis, Inc.
Via Business Wire
6 Analysts Have This to Say About Exelixis
Via Benzinga
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
From Exelixis, Inc.
Via Business Wire
NASDAQ:EXEL, a growth stock which is not overvalued.
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Where Exelixis Stands With Analysts
Via Benzinga
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
From Arcus Biosciences
Via Business Wire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
From Exelixis, Inc.
Via Business Wire
Earnings Outlook For Exelixis
Via Benzinga
Is Exelixis Stock a Buy Now?
There is one key reason to consider the stock. 
Via The Motley Fool
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
From Exelixis, Inc.
Via Business Wire
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
3 Biotech Stocks With the Strongest Clinical Pipelines
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high. 
Via The Motley Fool
Topics Stocks
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Why Exelixis Stock Is Trading Lower Today
Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in 
Via Benzinga
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
From Exelixis, Inc.
Via Business Wire
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue. 
Via The Motley Fool
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.